The distribution and function of GDE2, a regulator of spinal motor neuron survival, are disrupted in Amyotrophic Lateral Sclerosis

Anna Westerhaus1, Thea Joseph2, Alison J. Meyers2, Yura Jang3, Chan Hyun Na3, Clinton Cave2* and Shanthini Sockanathan1*

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects the viability of upper and lower motor neurons. Current options for treatment are limited, necessitating deeper understanding of the mechanisms underlying ALS pathogenesis. Glycerophosphodiester phosphodiesterase 2 (GDE2 or GDPD5) is a six-transmembrane protein that acts on the cell surface to cleave the glycosylphosphatidylinositol (GPI)-anchor that tethers some proteins to the membrane. GDE2 is required for the survival of spinal motor neurons but whether GDE2 neuroprotective activity is disrupted in ALS is not known. We utilized a combination of mouse models and patient post-mortem samples to evaluate GDE2 functionality in ALS. Haplogenetic reduction of GDE2 exacerbated motor neuron degeneration and loss in SOD1G93A mice but not in control SOD1WT transgenic animals, indicating that GDE2 neuroprotective function is diminished in the context of SOD1G93A. In tissue samples from patients with ALS, total levels of GDE2 protein were equivalent to healthy controls; however, membrane levels of GDE2 were substantially reduced. Indeed, GDE2 was found to aberrantly accumulate in intracellular compartments of ALS motor cortex, consistent with a disruption of GDE2 function at the cell surface. Supporting the impairment of GDE2 activity in ALS, tandem-mass-tag mass spectrometry revealed a pronounced reduction of GPI-anchored proteins released into the CSF of patients with ALS compared with control patients. Taken together, this study provides cellular and biochemical evidence that GDE2 distribution and activity is disrupted in ALS, supporting the notion that the failure of GDE2-dependent neuroprotective pathways contributes to neurodegeneration and motor neuron loss in disease. These observations highlight the dysregulation of GPI-anchored protein pathways as candidate mediators of disease onset and progression and accordingly, provide new insight into the mechanisms underlying ALS pathogenesis.

Keywords: GDE2, Motor neuron, Neurodegeneration, GPI-anchored proteins, ALS

Background

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that primarily affects upper (corticospinal) and lower (spinal) motor neurons, ultimately resulting in muscle weakness, paralysis and death [1–5]. Onset of symptoms typically arises in mid-life, with survival in most cases limited to 2–4 years. Approximately 10% of patients with ALS show a genetic component that is inherited in an autosomal dominant fashion and are defined as having familial ALS (FALS) [6].
The remaining 90% of cases have no known family history of ALS and are designated as having sporadic disease (sALS) [6]. There is no cure for ALS. Current treatment options are limited, with approved medications Riluzole and Edaravone providing modest benefits in few patients [7, 8]. Accordingly, there is a pressing need to deepen our understanding of the mechanisms underlying ALS pathogenesis to accelerate the development of better treatments. The study of disease-associated mutations, the most common of which occur in SOD1 (Superoxide dismutase 1), C9orf72 (C9 open reading frame 72), FUS (Fused in sarcoma) and TARDBP (Transactive response DNA binding protein 43 kDa) indicate that abnormalities in pathways downstream of these mutated proteins are causal for neurodegeneration in ALS [9–13]. However, whether endogenous neuroprotective pathways that normally maintain neuronal viability throughout life are targeted in disease and contribute to disease pathology remains unclear. Addressing this gap in knowledge may help clarify the complexities of ALS pathologies, provide new insight into disease etiology and progression, and aid in the development of more effective treatments.

Recent studies have identified separate roles for Glycerophosphodiester phosphodiesterase 2 (GDE2, also known as GDPD5) in embryonic spinal motor neuron development and for motor neuron survival in the adult organism [14–17]. GDE2 is a six-transmembrane protein that together with its family members GDE3 and GDE6, are the only known enzymes in vertebrates that function on the cell surface to cleave the glycosylphosphatidylinositol (GPI)-anchor that tethers some proteins to the membrane [16, 18–22]. GDE2 is also suggested to metabolize glycerophosphocholine; however, this observation is observed in kidney cells and its relevance to the nervous system is still unclear [16, 23]. GDE2 is expressed in neurons, in subsets of terminally differentiated oligodendrocytes and in the vascular endothelium, and its expression is complementary to GDE3 (or GDPD2), which is expressed in oligodendrocyte precursor cells (OPCs) and astrocytes [15, 17, 24–26]. The expression of GDE6 in the mammalian nervous system has not been reported. During embryonic neurogenesis, GDE2 is required for the production of late-born motor neuron subtypes of the Lateral Motor Column (LMC) that innervate the limb musculature [15]. Mechanistically, GDE2 drives motor neuron differentiation by downregulating Notch signaling through GPI-anchor cleavage and release of the metalloprotease inhibitor RECK (Reversion inducing signaling through GPI-anchor cleavage and release of the metalloprotease inhibitor RECK) from the cell surface [16]. In the adult spinal cord, GDE2 function is essential for motor neuron viability across spinal motor columns [17]. Mice lacking GDE2 (Gde2−/−) exhibit age-progressive neurodegeneration with characteristic increases in vacuolization, cytoskeletal protein accumulation, microgliosis, and lipofuscin deposition followed by astrogliosis and motor neuron loss [17]. These deficits are accompanied by peripheral restructuring and a progressive erosion of sensorimotor function. Timed genetic ablation of GDE2 that preserves its embryonic roles in motor neuron generation, phenocopied the neurodegenerative changes and motor neuron loss observed in aged Gde2−/− animals, indicating that GDE2’s role in motor neuron survival is distinct from its function in embryonic neurogenesis [17]. Thus, GDE2 encodes a physiological pathway that is required for motor neuron survival in the adult spinal cord.

The neurodegenerative changes observed in Gde2−/− animals show pronounced overlap with degenerative hallmarks observed in the spinal cords of mouse models of ALS such as the SOD1G93A animal, which harbors a transgene of the human SOD1 gene carrying the G93A mutation associated with fALS [27–29]. Although the progression of neurodegeneration and motor neuron loss in SOD1G93A transgenic mice is more rapid, SOD1G93A animals exhibit shared neurodegenerative changes with Gde2−/− mice, specifically, increased vacuolization, inclusions of cytoskeletal proteins, and inflammation [28, 29]. Interestingly, the release of members of the heparan sulfate proteoglycan glypican (GPC) family, which are established GPI-anchored substrates of GDE2, is reduced in SOD1G93A lumbar spinal cords, suggesting an erosion of GDE2 function in this animal model [16, 17, 21]. Based on these observations, we hypothesize that GDE2 neuroprotective activity towards spinal motor neurons is diminished in the context of disease pathology, and that this impairment could contribute to disease progression in ALS. However, whether GDE2 function is impaired in ALS has not been addressed.

Here, we utilize the SOD1G93A mouse model of fALS combined with samples from patients with ALS to investigate GDE2 functionality in ALS. Genetic reduction of GDE2 exacerbated neurodegenerative changes in SOD1G93A animals but not SOD1WT controls, indicating GDE2 hypofunction in SOD1G93A spinal cords. Analysis of GDE2 expression in postmortem motor cortex samples comparing control patients and patients with ALS showed a pronounced reduction of GDE2 in membrane fractions prepared from patients with ALS although total levels of GDE2 were equivalent between the two groups. Strikingly, GDE2 was found to accumulate in intracellular compartments in sectioned samples of motor cortex of patients with ALS suggesting
the disruption of GDE2 activity in ALS. Supporting this notion, unbiased proteomic analysis of cerebrospinal fluid (CSF) samples from healthy controls and patients with ALS show a disproportionate reduction of released GPI-anchored proteins in CSF from patients with ALS. Taken together, these observations suggest that GDE2 function is disrupted in ALS, an outcome consistent with the model that the failure of GDE2-regulated neuroprotective pathways contributes to motor neuron degenerative pathologies in ALS.

Methods
Animals
Mice were bred and maintained in accordance with approved Johns Hopkins University Institutional Animal Care and Use Committee protocols. Gde2 heterozygous (Gde2±) mice were bred, maintained, and genotyped as described previously [15]. SOD1G93A (Jackson Laboratory Strain #002,726), and SOD1WT (Jackson Laboratory Strain #002,297) animals were bred, maintained, and genotyped as described previously [17].

Human samples
Postmortem tissue: Frozen postmortem motor cortex samples and paraffin embedded sections of postmortem motor cortex were obtained from the Target ALS Multicenter Postmortem Tissue Core. Sections of postmortem motor cortex were also obtained from the Johns Hopkins Brain Resource Center. All procedures were performed with appropriate Health Insurance Portability and Accountability Act (HIPAA)-approved autopsy consents. The demographics of postmortem samples used in this study are provided in Additional File 1: Supplementary Table 1.

CSF samples: CSF samples from 11 control individuals and 20 patients with ALS were obtained from the Northeast Amyotrophic Lateral Sclerosis (NEALS) consortium. Nine additional CSF samples from control individuals were provided by the Advancing Research and Treatment for Frontotemporal Lobar Degeneration Research Consortium (ARTFL). Study participants provided written informed consent, and all procedures were approved by the respective Institutional Review Boards (IRB). The demographics of CSF samples used in this study are provided in Additional File 2: Supplementary Table 2.

Immunohistochemistry
Paraffin sections (mouse)
Immunostaining was performed as previously described [17]. Briefly, slides were deparaffinized in Xylenes, rehydrated, and washed with Phosphate Buffered Saline (PBS) containing 0.3% Triton-X-100 (PBST). Microwave antigen retrieval in 10 mM Sodium citrate followed by blocking in 5% Normal Goat Serum was performed.

Paraffin sections (human)
Human motor cortex sections were deparaffinized in Xylenes, then rehydrated in 100% ethanol, 95% ethanol, 70% ethanol, and rinsed with water [30]. Permeabilization was performed with 0.3% PBST followed by antigen retrieval in 10 mM Sodium Citrate with 0.5% Tween-20 (pH 6.0) in a 95 °C water bath. Sections were then washed in PBS followed by overnight blocking at 4 °C in 5% Bovine Serum Albumin (BSA). GDE2 primary antibody (cSS1[30], Covance,1:500) was diluted in 1% BSA and incubated overnight at 4 °C. After blocking endogenous peroxidases with 0.3% hydrogen peroxide and washing with PBS, tissue sections were incubated with horseradish peroxidase (HRP)-conjugated donkey anti-chicken secondary antibody (Jackson ImmunoResearch, 1:500) diluted in 1% BSA for 1 h at room temperature (RT). Sections were washed with PBS, and 3,3′-Diaminobenzidine solution (Sigma-Aldrich, D4168-50) was applied to sections for visualization. Sections were then washed and mounted with ProLong Antifade Gold with DAPI (ThermoFisher, P36931).

Primary antibodies
Rabbit Anti-Iba1 (Wako 019–19,741, 1:250), Mouse Anti GFAP (BD 556,328, 1:250), Mouse Anti-phospho-Neurofilament H (Calbiochem NE1022, 1:250), Rabbit Anti-Peripherin (Millipore Sigma AB1530, 1:250), and Chicken anti-human GDE2 (cSS1[30], Covance, 1:500).

Secondary antibodies
Jackson ImmunoResearch Goat Anti-Mouse Alexa 488 (115–545-166), Goat Anti Rabbit Alexa 594 (111–585-144), and Peroxidase-conjugated Donkey Anti-Chicken IgY (703–035-155). Brightfield and epifluorescence images were collected at 20× using a Zeiss Axioskop 2 upright microscope or a Keyence BZ-X710 epifluorescence microscope. Confocal imaging was performed with an Olympus FV3000 Laser scanning confocal microscope. Images were analyzed using ImageJ (NIH) and Matlab Image Processing (Mathworks).

Image quantification
SOD Pathology (mouse)
The soma and vacuole sizes were calculated from brightfield H&E images. Custom Matlab imaging software was used to threshold and binarize the images to quantify the vacuolization and motor neuron number. A minimum of 12 ventral horns from lumbar spinal cord were analyzed per animal. Neuronal soma were
distinguished from glia based on their location in the ventral grey matter and minimum size of 60 μm². We analyzed a minimum of 900 neurons per genetic condition. To isolate large diameter vacuoles indicative of degeneration, vacuoles required a minimum size of 75 μm² to be included in the dataset. Vacuole counts were binned in 3.75 μm² intervals to create a frequency histogram. The number of vacuoles in each bin plus all smaller bins was calculated as a percentage of all detected vacuoles and graphed as a cumulative probability distribution. The distributions of neuronal sizes were compared with an independent samples Kruskal–Wallis Test, and vacuole size distributions were compared with the Kolmogorov–Smirnov test. Manual counts of the mean number of cytoskeletal inclusions were compared with each batch including a master pool (MP) sample containing an equal volume of all CSF samples for normalization between batches. The CSF samples were mixed with a urea buffer, composed of 10 M urea/20 mM tris (2-Carboxyethyl) phosphine hydrochloride (TCEP)/80 mM chloroacetamide (CAA) in 100 mM triethylammonium bicarbonate (TEAB), at a one-to-one ratio. Samples were incubated for 1 h at RT for reduction and alkylation. Protein digestion was carried out using LysC (lysyl endopeptidase mass spectrometry (MS) grade, Fujifilm Wako Pure Chemical Industries Co., Ltd., Osaka, Japan) at a one-to-fifty (w/w) ratio for 3 h at 37 °C and subsequently with trypsin digestion (sequencing grade modified trypsin, Promega, Fitchburg, WI, USA) at a one-to-fifty (w/w) ratio at 37 °C overnight after diluting the concentration of urea from 5 to 2 M by adding 50 mM TEAB. Peptides were desalted using C₁₈ StageTips (3 M Empore™; 3 M, St. Paul, MN, USA) after acidifying with 1% trifluoroacetic acid (TFA) to the final concentration. The eluted solution containing peptides was dried with a Savant SPD121P SpeedVac concentrator (Thermo Fisher Scientific, San Jose CA) and then stored at −80 °C before use.

For tandem mass tag (TMT)-based quantitative MS, the digested peptides from CSF samples were labeled using a BCA Protein Assay kit (ThermoFisher, 23,225).

**Immunoblotting**

Samples were subject to reducing SDS-PAGE using 7.5 or 10% Criterion TGX Precast Gels (Bio-Rad Laboratories) in tris/glycine buffer, transferred onto polyvinylidene difluoride membranes at 100 V for 70 min, and blocked with 5% milk in tris-buffered saline containing 0.3% Tween-20 (TBST) for 2–3 h at RT. Membranes were then incubated with primary antibodies diluted in 5% milk in TBST overnight at 4 °C. Membranes were then incubated with primary antibodies diluted in 5% milk in TBST and incubated for 1 h at RT. Membranes were developed using the KwikQuant Imager (Kindle Biosciences) after incubation with enhanced chemiluminescence substrate (Kindle Biosciences, R1004). Imaged blots were analyzed using ImageJ software (NIH).

**Primary antibodies**

Chicken anti-human GDE2 (cSS1, [30] Covance, 1:1000), Rabbit anti-NA/K ATPase (Abcam, ab76020, 1:100,000), and Rabbit anti-GAPDH (Cell Signaling, 8884, 1:5000).

Secondary Antibodies: Peroxidase-conjugated Donkey Anti-Chicken IgY (Jackson ImmunoResearch, 703–035-155, 1:10,000) and Anti-Rabbit IgG-HRP (Kindle Biosciences, R1006, 1:10,000).

**CSF sample preparation and trypsin digestion for MS experiments**

Four experimental batches of 10 samples were examined, with each batch including a master pool (MP) sample containing an equal volume of all CSF samples for normalization between batches. The CSF samples were mixed with a urea buffer, composed of 10 M urea/20 mM tris (2-Carboxyethyl) phosphine hydrochloride (TCEP)/80 mM chloroacetamide (CAA) in 100 mM triethylammonium bicarbonate (TEAB), at a one-to-one ratio. Samples were incubated for 1 h at RT for reduction and alkylation. Protein digestion was carried out using LysC (lysyl endopeptidase mass spectrometry (MS) grade, Fujifilm Wako Pure Chemical Industries Co., Ltd., Osaka, Japan) at a one-to-fifty (w/w) ratio for 3 h at 37 °C and subsequently with trypsin digestion (sequencing grade modified trypsin, Promega, Fitchburg, WI, USA) at a one-to-fifty (w/w) ratio at 37 °C overnight after diluting the concentration of urea from 5 to 2 M by adding 50 mM TEAB. Peptides were desalted using C₁₈ StageTips (3 M Empore™; 3 M, St. Paul, MN, USA) after acidifying with 1% trifluoroacetic acid (TFA) to the final concentration. The eluted solution containing peptides was dried with a Savant SPD121P SpeedVac concentrator (Thermo Fisher Scientific, San Jose CA) and then stored at −80 °C before use.

**Western blot analysis**

**Lysate preparation**

Human motor cortex samples were either sonicated in RIPA lysis buffer containing protease inhibitor cocktail (Sigma, P8340) or partitioned into detergent-poor and detergent-rich fractions with Triton-X-114 (Sigma, X114) as previously described [16]. Briefly, 2% Triton-X-114 was pre-conditioned in 100 mM Tris–HCl, pH 7.4, 150 mM NaCl buffer. The frozen tissues were sonicated in 1% Triton-X-114 containing protease inhibitor cocktail, followed by centrifugation (16,000 × g, 2 × 10 min, 4 °C). Detergent-rich and detergent-poor phases were separated by incubating the lysates at 30 °C for 10 min. After centrifugation (3000 × g, 3 min, RT), the detergent-rich pellet was collected for analysis of membrane-bound proteins. Batches of human samples were processed at the same time to minimize variability between samples, and protein amounts were standardized using a BCA Protein Assay kit (ThermoFisher, 23,225).
with 11-plex TMT reagents following the manufacturer’s instructions (Thermo Fisher Scientific). The MP sample was labeled with 131C, and CSFs from ALS and control individuals were labeled with the rest of the TMT tags. The labeling reaction was performed for 1 h at RT after mixing each peptide sample in 100 mM TEAB with TMT reagent in acetonitrile (ACN, HPLC grade), and then quenched by adding 1/10 volume of 1 M Tris–HCl (pH 8.0). The TMT labeled peptides were pooled, resuspended with 10 mM TEAB, and then subjected to basic pH reversed-phase liquid chromatography (bRPLC) fractionation to generate fractions on an Agilent 1260 offline HPLC system (Agilent Technologies, Santa Clara, CA, USA), which includes a binary pump, variable wavelength detector, an autosampler, and an automatic fraction collector. The pooled samples were reconstituted in solvent A (10 mM TEAB, pH 8.5) and loaded onto Agilent 300 Extend-C18 column (5 μm, 4.6 mm × 250 mm, Agilent Technologies). Peptides were resolved using a gradient of solvent B (10 mM TEAB in 90% ACN, pH 8.5) at a flow rate of 0.3 mL/min over 90 min, collecting 96 fractions. Subsequently, the fractions were concatenated into 24 fractions followed by vacuum drying using a SpeedVac (Thermo Fisher Scientific, San Jose, CA, USA). The dried peptides were suspended in 0.5% formic acid (FA), and 30% of each fraction was injected for MS analysis.

**LC–MS/MS analysis**

Peptide samples were analyzed on an Orbitrap Fusion Lumos Tribrid mass spectrometer interfaced with an Ultimate 3000 RSLCnano nanoflow liquid chromatography (LC) system (Thermo Fisher Scientific). The dried 24 fractionated peptides were reconstituted in 0.5% FA and then loaded onto a trap column (Acclaim™ PepMap™ 100 LC C18, 5 μm, 100 μm × 2 cm, Thermo Fisher Scientific) at a flow rate of 8 μL/min. Peptides were separated on an analytical column (Easy-Spray™ PepMap™ RSLC C18, 2 μm, 75 μm × 50 cm, Thermo Fisher Scientific) at a flow rate of 0.3 μL/min using a linear gradient with mobile phases consisted of 0.1% FA in water and in 95% ACN. The total run time was 120 min. The mass spectrometer was operated in a data-dependent acquisition mode. The MS1 (precursor mass) scan range for a full survey scan was acquired from 300 to 1,800 m/z (mass-to-charge ratio) in the “top speed” setting with a resolution of 120,000 at an m/z of 200. The AGC target for MS1 was set as 1 × 10^6 and the maximum injection time was 50 ms. The most intense ions with charge states of 2 to 5 were isolated in a 3-s cycle, fragmented using higher-energy collisional dissociation (HCD) fragmentation with 35% normalized collision energy, and detected at a mass resolution of 50,000 at an m/z of 200. The AGC target for MS/MS (MS2, fragment mass) was set as 5 × 10^4 and the ion filling time was 100 ms. The precursor isolation window was set to 1.6 m/z with a 0.4 m/z offset. The dynamic exclusion was set for 30 s, and singly charged ions were rejected. Internal calibration was carried out using the lock mass option (m/z 445.120025) from ambient air.

**Database searches for peptide and protein identification**

The acquired tandem MS data were searched against the human UniProt database (released in May 2018, containing protein entries with common contaminants) using the SEQUEST algorithm through the Thermo Proteome Discoverer platform (version 2.2.0.388, Thermo Fisher Scientific) for quantitation and identification. During MS/MS preprocessing, the top 10 peaks in each window of 100 m/z were selected for database searches. The search parameters included two maximum missed-cleavage sites by trypsin as a proteolytic enzyme. Carbamidomethyl (+57.02146 Da) at cysteine and TMT reagents (+229.162932 Da) modification at N-terminus of peptide and lysine residues were set as fixed modifications while oxidation (+15.99492 Da) of methionine was a variable modification. For MS data, MS1 error tolerance was set to 10 ppm and the MS/MS error tolerance to 0.02 Da. The minimum peptide length was set to 6 amino acids, and proteins identified by one peptide were filtered out. Both peptides and proteins were filtered at a 1% false discovery rate (FDR). The protein quantification was performed with the following parameters and methods. The most confident centroid option was used for the integration mode while the reporter ion tolerance was set to 20 ppm. MS order was set to MS2. The activation type was set to HCD. The quantification value correction was disabled. Both unique and razor peptides were used for peptide quantification. Protein groups were considered for peptide uniqueness. Missing intensity values were replaced with the minimum value. Reporter ion abundance was computed based on the signal-to-noise ratio. Quantification value corrections for isobaric tags were disabled. The co-isolation threshold was set to 50%. The average reporter signal-to-noise threshold was set to 50. Data normalization was disabled. Protein grouping was performed by applying strict parsimony principle as following: 1) all proteins that share the same set or subset of identified peptides were grouped, 2) protein groups that have no unique peptides among the considered peptides were filtered out, 3) Proteome Discoverer iterated through all spectra and selected which peptide-spectrum match (PSM) to use in ambiguous cases to make a protein group with the highest number of unambiguous and unique peptides, and 4) final
protein groups were generated. The Proteome Discoverer summed all the reporter ion abundances of PSMs for the corresponding proteins in a TMT run.

**Statistical analyses of the results from discovery proteomics**

Statistical analysis was conducted with the Perseus software package (version 1.6.0.7). Protein abundance values across the samples were divided by those of MP included in each batch, followed by dividing values of each sample by their median value. After log2-transformation of all the values, values across proteins were z-score-transformed. The fold changes between the comparison groups were calculated by dividing the average abundance values across the samples of one group by the ones of another group. The P values between the comparison groups were calculated with the 2-tailed Student’s t test. The q-values for the volcano plots were calculated by significance analysis of microarrays (SAM) and a permutation-based FDR estimation [31].

**Results**

**GDE2 reduction exacerbates neurodegenerative changes in SOD1G93A mouse models**

To assess GDE2 function in a disease context, we wanted to ascertain whether known degenerative conditions could reduce GDE2’s neuroprotective capacity towards spinal motor neurons. SOD1G93A transgenic animals undergo rapid spinal neurodegeneration that includes vacuolization, inclusions of neurofilament proteins, and inflammation, which leads to spinal motor neuron death [28, 29]. Despite a more prolonged progression and later onset of motor neuron death, degeneration in Gde2−/− mice has considerable phenotypic overlap with the SOD1G93A model [17]. To test whether the SOD1G93A disease state hinders GDE2 function, we compared Gde2+/+;SOD1G93A versus Gde2−/−;SOD1G93A animals. Gde2 heterozygotes do not exhibit spinal pathology [17]; accordingly, any worsening of pathology in the Gde2−/−;SOD1G93A would suggest that SOD1G93A disease conditions diminish GDE2 function below the threshold for haplosufficiency.

At 14 weeks of age, Gde2+/−;SOD1G93A animals present markedly worsened neuropathology compared to Gde2+/+;SOD1G93A controls (Fig. 1). As neurons degenerate, they shrink in size, succumbing to external phagocytosis and internal apoptotic pathways that produce a pyknotic morphology [32]. Gde2−/−;SOD1G93A mice have significantly reduced neuronal somal size, with a median area of 108 μm² compared to 125 μm² in Gde2+/−;SOD1G93A controls (Fig. 1A, B and E). Importantly, neuronal size is unchanged between Gde2 wild-types and heterozygotes in the background of the control SOD1WT transgene, which does not harbor the disease associated glycine-to-alanine mutation (Fig. 1C-E). Additionally, extracellular vacuolization is more severe in the ventral horn of Gde2+/−;SOD1G93A mice, with an 8% increase in median vacuole diameter (Fig. 1F).

Cytoskeletal accumulations are a prominent hallmark of ALS [33], and spinal motor neuron cell bodies and axons of SOD1G93A animals show pronounced inclusions of peripherin and phosphorylated neurofilament-H (phospho-NFH) proteins (Fig. 2A and E). Aged Gde2−/− animals exhibit similar accumulation of peripherin and phospho-NFH at later stages of adulthood but Gde2+/− animals do not [17]. Strikingly, Gde2+/−;SOD1G93A spinal cords show a robust increase in the number of peripherin (3.2 ± 0.8 versus 1.4 ± 0.4) and phospho-NFH (1.6 ± 0.5 versus 0.4 ± 0.2) inclusions in the ventral horn (Fig. 2B, F and M) at 14 weeks of age. In contrast, 14 week Gde2+/−;SOD1WT and Gde2−/−;SOD1WT tissues have no detectable cytoskeletal inclusions (Fig. 2C, D, G and H). The worsening of cellular neurodegenerative phenotypes when GDE2 function is disrupted in SOD1G93A animals but not SOD1WT mice reinforces the specificity of the effects between Gde2 and SOD1G93A.

Reactive gliosis encompasses the morphological thickening, proliferation, and aggregation of astrocytes and microglia upon injury or degeneration, and is indicative of inflammation [34, 35]. We stained sections of spinal cord for Glial Fibrillary Acidic Protein (GFAP) and Ionized calcium-binding adaptor protein-1 (Iba1) to measure astrogliosis and microgliosis, respectively (Fig. 2I and J). Iba1+ processes cover 10.4 ± 0.9% of Gde2+/−;SOD1G93A ventral grey matter while accounting for 5.8 ± 0.8% of controls (Fig. 2I, J, and N). GFAP area fraction did not show a significant increase, possibly due to the extreme astrogliosis already present in Gde2+/−;SOD1G93A controls (Fig. 2I, J and N). Evidence of astrogliosis and microgliosis was absent in age-matched Gde2+/−;SOD1WT and Gde2+/−;SOD1WT animals (Fig. 2K and L).

Collectively, these data indicate that GDE2 function is vulnerable to the degenerative stresses in the SOD1G93A animal, supporting the possibility that GDE2 hypofunctionality is a component of motor neuron pathologies associated with human neurodegenerative disease.

**GDE2 protein is abnormally distributed in patients with ALS**

Our finding that GDE2 neuroprotective function is impacted in SOD1G93A animals motivated us to determine if GDE2 function is disrupted in ALS. We first examined the amounts of GDE2 protein in protein extracts prepared from motor cortex of patients with sporadic ALS and healthy controls (Additional File 1: Supplementary Table 1) using
a previously validated antibody that specifically detects human (h) GDE2 (cSS1) [30]. Western blot analysis of protein extracts prepared from the motor cortex of healthy controls and patients with ALS detected equivalent amounts of hGDE2 protein between the two groups (Fig. 3A-B, Additional File 1: Supplementary Table 1). However, Western blot of membrane extracts prepared from postmortem motor cortex samples showed a pronounced reduction of hGDE2 in patients with ALS (Fig. 3C-D, Additional File 1: Supplementary Table 1). These observations suggest that although overall amounts of hGDE2 are unchanged between patient groups, the amounts of functional hGDE2 are reduced in the motor cortex of patients with ALS.

We next used the cSS1 antibody to examine the distribution of hGDE2 in sections of postmortem motor cortex from 7 control patients and 10 patients with ALS. Similar to previous studies, healthy controls showed hGDE2 protein expression in the neuropil and in the cell soma (Fig. 3E), with some cells exhibiting modest accumulation adjacent to the nucleus [30]. However, patients with ALS showed many cells with high levels of hGDE2 accumulation in intracellular compartments (Fig. 3E). These cells include cells with large diameter nuclei that correspond to neurons (Fig. 3E.1), cells with smaller diameter that are consistent with glial cells (Fig. 3E.2), and elongated cells that resemble blood vessels (Fig. 3E.3). These cell types align with the known expression profile of GDE2 in neurons, terminally differentiated oligodendroglia, and vascular endothelia [17, 24, 26]. Quantification of cells with pronounced hGDE2 accumulations showed that there was a robust increase in their numbers in patients with ALS compared with controls (Fig. 3F and Additional File 1: Supplementary Table 1).
These observations reveal that while total levels of hGDE2 are equivalent between controls and patients with ALS, hGDE2 distribution is disrupted with a reduction in membrane-bound hGDE2 and an increase in cytoplasmic hGDE2 accumulations. These abnormalities could imply that hGDE2 function is impaired in ALS.

Release of GPI-anchored proteins is reduced in CSF of patients with ALS

GDE2 acts at the cell surface to cleave the GPI-anchor that tethers some proteins to the plasma membrane and is one of three membrane proteins in vertebrates that regulate surface GPI-anchored protein activity via
this mechanism [16, 18, 21]. The reduction in membrane-bound hGDE2 and the corresponding accumulation of hGDE2 in intracellular compartments in patients with ALS suggests that hGDE2 function is disrupted in the context of ALS disease states. If this is the case, then the amount of released GPI-anchored proteins normally cleaved by hGDE2 should be reduced in patients with ALS compared with controls. GPI-anchored proteins that are released from the plasma membrane can partition into the cerebrospinal fluid (CSF). GDE2 is one of two surface GPI-anchor cleaving enzymes expressed in the nervous system; thus, disrupted GDE2 function should result in a reduction of the amount of GPI-anchored proteins in the CSF. To assess global changes in the amounts of GPI-anchored proteins in ALS, we measured the amount of GPI-anchored proteins in patient CSF using tandem-mass-tag (TMT) mass spectrometry (MS), which provides sensitive quantitative measurement of CSF proteins (Fig. 4A). We analyzed a total of 40 CSF samples from 20 control individuals and 20 patients with ALS (Additional File 2: Supplementary Table 2). The 40 samples were split into 4 batches of 10 and were labeled with an 11-plex TMT reagent, which allowed for multiplex running of 11 samples at a time. The master pool (MP), which is a pooled reference sample of equal volumes from all 40 CSF samples, was placed at the 11th channel of each 11-plex TMT experimental set for the purpose of normalization between batches (Fig. 4A). The TMT-labeled samples were pre-fractionated using a basic pH RPLC (reversed-phase liquid chromatography) system for more in-depth protein identification, followed by LC (liquid chromatography)-MS/MS analysis. We identified 3,038 proteins in total, of which 78 were GPI-anchored proteins (Additional File 3: Supplementary Table 3). Twenty-nine GPI-anchored proteins showed a q-value of < 0.1 (Table 1). Notably, amounts of these proteins were found to be decreased in CSF of patients with ALS compared with controls (Fig. 4B, Table 1 and Additional File 3: Supplementary Table 3). Further, searches of expression profiling databases reveal that 27 of the 29 proteins were expressed in cellular sites of GDE2 expression (Table 1). Taken together, these observations reveal a pattern of reduced GPI-anchored protein release in CSF of patients with ALS, correlating with the abnormal intracellular accumulation of GDE2 in ALS patient postmortem samples. These observations provide support that hGDE2 activity and function are disrupted in ALS.

Discussion

Neuronal viability throughout life is maintained through various cellular pathways that mitigate the detrimental consequences of insult and injury. Deeper understanding of how the disruption of these pro-survival pathways contribute to the onset and progression of neurodegenerative disease will provide insight into disease etiology and could inform the design of therapeutic strategies. Previous studies have established that GDE2 is required for the survival of spinal motor neurons but relevance of GDE2 dysfunction to ALS has not been examined [17]. Collectively, using the SOD1\textsuperscript{G93A} model of fALS, and patient tissue and CSF samples, we show here that GDE2 distribution and activity is disrupted in ALS. Haplogenetic reduction of GDE2 does not elicit neuropathology or motor neuron loss; however, in SOD1\textsuperscript{G93A} animals, genetic reduction of GDE2 resulted in pronounced exacerbation of neurodegenerative phenotypes in line with impaired GDE2 function in the context of disease pathology. Consistent with this logic, GDE2 was found to form intracellular accumulations in postmortem motor cortex of patients with ALS and the amounts of released GPI-anchored proteins in CSF of patients with ALS were reduced. These collective observations provide evidence that GDE2 function is disrupted in ALS, and suggest that GDE2 dysfunction contributes to neuropathologies associated with disease.

(See figure on next page.)

\textbf{Fig. 3} hGDE2 protein distribution is disrupted in ALS. A Western blot of protein extracts prepared from postmortem motor cortex of control (Ctl) and patients with ALS. GAPDH serves as a loading control. B Quantification of hGDE2 expression relative to GAPDH in total lysate shows no significant (ns) difference in hGDE2 expression between control and ALS patients. Graph represents mean ± SEM. Student’s t test (p = 0.6985), n = 3 Control, 6 ALS. C Western blot of Triton-X-114 membrane fractions of motor cortex from control individuals and patients with ALS. Na/K ATPase serves as a loading control and confirms the enrichment of membrane proteins in extracts. D Quantification of hGDE2 expression relative to Na/K ATPase in membrane extracts shows reduced hGDE2 expression in membrane fractions from ALS patients compared to control individuals. Graph represents mean ± SEM. Student’s t test (\*\*p = 0.0020), n = 3 Control, 6 ALS. E Immunohistochemical staining of postmortem human motor cortex sections of control individuals and patients with ALS. Arrows highlight different types of cells with high-intensity hGDE2 accumulations (black arrow = neuron, clear arrow = glial cell, black arrowhead = blood vessel). Representative images of GDE2 accumulations in different types of cells compared with control are highlighted in panels 1 (neuron), 2 (glial cell), and 3 (blood vessel). F Quantification of the number of high-intensity hGDE2 accumulations in cells from control and ALS sections shows a significant increase of high intensity accumulations of hGDE2 in ALS patients compared to controls. Total number of cells counted: Control = 831 and ALS = 2896. Graph represents mean ± SEM. Student’s t test (\*\*p = 0.0022), n = 7 Control, 10 ALS
Fig. 3 (See legend on previous page.)
Our observation that reducing GDE2 levels in SOD1G93A animals aggravates neurodegeneration suggests that GDE2 function is reduced below its threshold of haplosufficiency in disease conditions. Insight into the cellular basis of this dysfunction comes from our analysis of hGDE2 distribution in human postmortem tissues. In contrast to control patients, we find that in motor cortex of patients with ALS, hGDE2 is no longer expressed on the cell surface but instead aberrantly accumulates within cells. Structure–function studies in heterologous cells have shown that surface expression of GDE2 is critical for its GPI-anchor cleavage function [36]. Accordingly, intracellular accumulation of hGDE2 in ALS patient samples is suggestive of a failure of GDE2 enzymatic function in ALS. This notion is borne out by our proteomic studies that show a marked reduction in the amounts of GPI-anchored proteins released into CSF in patients with ALS compared with controls. Proteomic studies of brain extracts reveal that total amounts of GPI-anchored proteins are unchanged between control and ALS conditions [37]. In our study, 18 of these proteins were detected in CSF, and 13 were significantly reduced in ALS patient CSF (12 with q < 0.1; 1 with q > 0.1; all p < 0.05). These observations imply that the reduction in the amounts of GPI-anchored proteins in CSF from ALS patients that we observe, is a consequence of reduced release rather than a global loss of protein in disease conditions. GPI-anchored proteins can be released in the CSF by proteolytic cleavage in addition to cleavage at the GPI-anchor. However, because GDE2 and its family member GDE3 are the only known surface GPI-anchor cleaving enzymes in vertebrates that are expressed in the nervous system, we expect that six-transmembrane GDE protein activity would be a major contributor to the amounts of GPI-anchored proteins detected in the CSF. Added support for the concept that disrupted GDE2 enzymatic activity is linked to the intracellular accumulation of GDE2 comes from studies of GDE2 function in Alzheimer’s disease (AD) [30]. GDE2 promotes the non-amyloidogenic processing of the amyloid precursor protein APP by cleavage of the GPI-anchored protein RECK, an inhibitor of
the α-secretase ADAM10. In AD, hGDE2 shows pronounced intracellular accumulation in neurons, and this altered distribution is linked to the failed release of RECK and an increase in the amount of membrane RECK in AD patient brain [30]. In contrast, hGDE2 expression is not impaired in postmortem brain of patients with Huntington's disease (HD) and RECK release is equivalent to control patient samples [30]. These collective observations provide evidence that the disruption of hGDE2 surface expression in disease is synonymous with disrupted hGDE2 enzymatic activity. Combined with our previous observations that GDE2 is required for motor neuron survival [17], our observations support the notion that the failure of hGDE2 activity contributes to neuropathologies and motor neuron loss in ALS. Interestingly, RECK was not identified in the list of GPI-anchored proteins that are differentially expressed in ALS. Because RECK is implicated in Aβ production [30], this would be consistent with the model that GDE2 dysfunction impacts subsets of GPI-anchored proteins in different disease contexts.

Our biochemical analysis of hGDE2 reveals that total amounts of hGDE2 are equivalent between control and ALS postmortem tissues, but that hGDE2 is reduced in the membrane-fraction in the context of ALS. This suggests that hGDE2 is not degraded in disease; instead, rather than being targeted to the membrane, GDE2 may form aggregates within cells, possibly within intracellular compartments. Further studies are needed to determine if hGDE2 has the propensity to aggregate and what factors might drive its intracellular accumulation/aggregation. One potential mechanism

| Protein name                                      | Gene symbol | P value | q-value | Z-score (ALS/control) | Cell Type          |
|---------------------------------------------------|-------------|---------|---------|------------------------|--------------------|
| Acetylcholinesterase                              | ACHE        | 0.0040  | 0.0535  | −0.451                 | N, O               |
| Thy-1 membrane glycoprotein (Fragment)           | THY1        | 0.0037  | 0.0537  | −0.533                 | N, O, E            |
| Semaphorin-7A                                     | SEMA7A      | 0.0030  | 0.0573  | −0.674                 | N, O, MG           |
| Repulsive guidance molecule A                     | RGMA        | 0.0088  | 0.0576  | −0.547                 | N, A               |
| Netrin-G1                                         | NTN1G1      | 0.0033  | 0.0580  | −0.566                 | N, O               |
| Carbonic anhydrase 4                              | CA4         | 0.0069  | 0.0596  | −0.532                 | N, MG, E           |
| RGM domain family member B                        | RGM1B       | 0.0046  | 0.0597  | −0.569                 | N, O, A, E         |
| Neuronal growth regulator 1                       | NEGR1       | 0.0023  | 0.0605  | −0.565                 | N, O, A, E         |
| Ephrin-A3                                         | EFNA3       | 0.0149  | 0.0618  | −0.571                 | N                  |
| Reticulon-4 receptor (Fragment)                   | RTN4R       | 0.0089  | 0.0625  | −0.593                 | N, A               |
| Limbic system-associated membrane protein (Fragment) | LSAMP      | 0.0103  | 0.0715  | −0.390                 | N, O, A            |
| Contactin-1                                       | CNTN1       | 0.0014  | 0.0735  | −0.337                 | N, O, A            |
| Cadherin-13                                       | CDH13       | 0.0317  | 0.0736  | −0.569                 | N, O               |
| Oligodendrocyte-myelin glycoprotein               | OMG         | 0.0021  | 0.0750  | −0.663                 | N, O, A            |
| Contactin-4                                       | CNTN4       | 0.0064  | 0.0760  | −0.401                 | N, O               |
| Low affinity immunoglobulin gamma Fc region receptor III-B | FCGR3B | 0.0514  | 0.0771  | −0.922                 | MG                 |
| Ciliary neurotrophic factor receptor subunit alpha | CNTRFR      | 0.0082  | 0.0773  | −0.377                 | A                  |
| Reticulon-4 receptor-like 1                       | RTN4RL1     | 0.0245  | 0.0816  | −0.509                 | N                  |
| Brevican core protein                             | BCAN        | 0.0178  | 0.0845  | −0.460                 | A, O               |
| Reticulon-4 receptor-like 2                       | RTN4RL2     | 0.0006  | 0.0860  | −0.677                 | N, O               |
| Opioid-binding protein/cell adhesion molecule     | OPCML       | 0.0278  | 0.0877  | −0.419                 | N, O, E            |
| Glypican-1                                        | GPC1        | 0.0151  | 0.0904  | −0.355                 | N, A               |
| Neuritin                                          | NNR1        | 0.0419  | 0.0923  | −0.465                 | N, O, E            |
| Contactin-3                                       | CNTN3       | 0.0197  | 0.0941  | −0.379                 | N, O               |
| Ephrin-A5                                         | EFNA5       | 0.0459  | 0.0967  | −0.463                 | N, A               |
| GDNF family receptor alpha-2                     | GFRA2       | 0.0432  | 0.0969  | −0.527                 | N                  |
| GPI-anchored high density lipoprotein-binding protein 1 | GPPIHBP1 | 0.0905  | 0.0974  | −0.996                 | O, E               |
| Contactin-6                                       | CNTN6       | 0.0317  | 0.0981  | −0.376                 | N, O               |
| Neural cell adhesion molecule 1                   | NCAM1       | 0.0160  | 0.0991  | −0.319                 | N, O, A            |
that could lead to the intracellular accumulation of GDE2 is the state of cellular redox. GDE2 trafficking to the plasma membrane is normally regulated by the thiol-redox state of two cysteine residues located within its extracellular glycerophosphodiester phosphodiesterase (GDPD) domain [38]. Under oxidative conditions, the ER-resident peroxiredoxin, Prdx4, oxidizes these residues to inhibit GDE2 trafficking to the cell surface, which sequesters GDE2 within the cell [38]. Accordingly, it is plausible that elevated oxidative states observed in disease could block the efficient trafficking of GDE2 to the cell surface, resulting in the intracellular buildup of GDE2 and the erosion of GDE2 function over time.

Studies in human postmortem tissue, mouse models and induced pluripotent stem cells (iPSCs) suggest that in addition to neurons, multiple cell types such as microglia, oligodendrocytes and astrocytes, contribute to neurodegeneration in ALS [39]. For example, mosaic analysis and cell-specific genetic deletions in SOD1 animal models of fALS suggest that neurons and glia have different contributions to disease onset and progression; however, the mechanisms involved are still unclear [39–44]. Nevertheless, these observations have led to the understanding that ALS is a complex multifactorial disease involving non-cell autonomous mechanisms that ultimately lead to the death of motor neurons and interneurons in the brain and spinal cord. GDE2 is expressed in neurons, terminally differentiated oligodendrocytes and cells of the vascular endothelium [17, 24, 26]. Interestingly, aberrant localization of GDE2 was detected in all of these cell types in the motor cortex of ALS patients. Future studies to examine the cell specific requirements of GDE2 in motor neuron survival will be an important first step in defining the cellular and molecular pathways by which GDE2 regulates neuronal viability.

GPI-anchor cleavage is central to GDE2 function; thus, it is likely that GDE2 regulates the function of specific GPI-anchored protein substrates to mediate neuronal survival. The identities of these proteins are not known but potential candidates that are disease-relevant to ALS would include GPI-anchored proteins that are significantly decreased in the CSF of ALS patients and are expressed in the same cell types as GDE2. The majority of these proteins we have identified (27/29) satisfy these criteria (Table 1), including GPC1, a known substrate of GDE2, whose release is also decreased in spinal cord extracts of SOD1G93A mice [17]. Notably, 1 of the 29 GPI-anchored proteins identified, CNTFRα, is an astrocyte-specific protein in human brain that is reduced in ALS patient CSF [26]. While GDE2 is not expressed in astrocytes, astrocytes are the main site of GDE3 expression and CNTFRα is a substrate of GDE3 [17, 24, 25]. This raises the possibility that GDE3 function is compromised in ALS, although roles for GDE3 in neurodegeneration have not been established. In addition to providing an entry-point to disease-relevant mechanistic studies of motor neuron survival, our observation that the partitioning of multiple GPI-anchored proteins to the CSF is reduced in ALS indicates potential for their use as disease biomarkers. Future analysis of GPI-anchored protein function and release in ALS could provide new opportunities in clarifying pathogenic mechanisms of ALS and for the development of functional biomarkers of disease.

Conclusions

Studies in mouse models have established that GDE2 is required for the survival of spinal motor neurons in the adult nervous system. Here, we utilize a combination of ALS mouse models and human samples to examine GDE2 in ALS. Haplogenetic reduction of GDE2 in fALS mouse models of fALS exacerbates motor neuron degeneration consistent with impaired GDE2 function in pathological contexts. Analysis of hGDE2 protein in human postmortem samples reveals that in ALS, membrane levels of hGDE2 are reduced and that hGDE2 shows abnormal intracellular accumulation. Consistent with disrupted hGDE2 function, the amounts of released GPI-anchored proteins are reduced in CSF of patients with ALS compared with control individuals. These observations suggest that GDE2 function is disrupted in ALS, raising the notion that GDE2's neuroprotective function is compromised in the context of disease and may contribute to neurodegenerative pathologies in ALS through altered regulation of GPI-anchored protein activity.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40478-022-01376-x.

Additional file 1. Supplementary Table 1: Patient Demographics for postmortem motor cortex samples.

Additional file 2. Supplementary Table 2: Patient Demographics for samples used in TMT studies.

Additional file 3. Supplementary Table 3: List of differential GPI-anchored proteins detected between ALS and control CSF.

Acknowledgements

We thank Nathalie Spita and Swati Agarwal for initial observations, members of the Sockanathan lab for discussions, and members of the Cave lab, Madeline McKean and Alison Wheeler for discussions.

Author contributions

AW, CC and SS conceived the study, designed experiments, performed data analysis and wrote the manuscript. AW performed histology, western blots and data analysis for studies involving human tissue. TJ, AM, and
CC performed histology and data analysis for mouse studies. CHN and YJ performed the TMT-tandem mass tag studies and carried out data analysis. All authors read and approved the final manuscript.

Funding
This work was funded by grants from the Muscular Dystrophy Association, the Robert Packard Center for ALS Research, and ALSFindingACure to SS, National Science Foundation grant #2018114 to CC, and a shared instrumentation NIH grant (S10OD021844). AW was supported by a National Institutes of Health (NIH) Ruth L. Kirschstein Predoctoral Individual Fellowship (F31) AG072745 and through an NIH grant T32 GM07445 (Biochemistry, Cellular and Molecular Biology Graduate program).

Availability of Data and Materials
The datasets supporting the conclusions of this article are included within the article and its additional files.

Declarations

Ethics approval and Consent to participate
Animals were maintained and used in accordance with approved Johns Hopkins University Institutional Animal Care and Use Committee (IACUC) protocols. All procedures for the collection and distribution of human postmortem samples were performed with appropriate HIPAA-approved autopsy consents. Study participants for CSF collection provided written informed consent, and all procedures were approved by the respective Institutional Review Boards (IRB).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 The Solomon Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, PCTB1004, 725 N. Wolfe Street, Baltimore, MD 21205, USA.  
2 Neuroscience Program, Middlebury College, 276 Biscentennial Way, Middlebury, VT 05753, USA.  
3 Department of Neurology, Institute for Cell Engineering, Johns Hopkins University School of Medicine, MRB 706, 733 N. Broadway, Baltimore, MD 21205, USA.

Received: 17 March 2022 Accepted: 25 April 2022
Published online: 12 May 2022

References
1. Rowland LP, Shneider NA (2001) Amyotrophic lateral sclerosis. N Engl J Med 344:1688–1700
2. Mitchell JD, Borasio GD (2007) Amyotrophic lateral sclerosis. Lancet 369:2031–2041
3. Rothstein JD (2009) Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 65(Suppl 1):S3-9
4. Kriemman MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zojing MC (2011) Amyotrophic lateral sclerosis. Lancet 377:942–955
5. Ajroud-Driss S, Siddique T (2015) Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim Biophys Acta 1852:679–684
6. Brown RH, Al-Chalabi A (2017) Amyotrophic Lateral Sclerosis. N Engl J Med 377:162–172
7. Miller RG, Mitchell JD, Lyon M, Moore DH (2007) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev: CD001447
8. Petrov D, Mansfield C, Moussy A, Hermine O (2017) ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Front Aging Neurosci 9:68
9. Taylor JP, Brown RH Jr, Cleveland DW (2016) Decoding ALS: from genes to mechanism. Nature 539:197–206
10. Da Cruz S, Cleveland DW (2011) Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr Opin Neurobiol 21:904–919
11. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O’Regan JP, Deng HK et al (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 363:59–62
12. Xu Z, Poidevin M, Li X, Li Y, Shu L, Nelson DL, Li H, Hales CM, Gearing M, Wingo TS, Jin P (2013) Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc Natl Acad Sci USA 110:7778–7783
13. Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Widensky S et al (2015) The Ckorf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525:56–61
14. Rao M, Sockanathan S (2005) Transmembrane protein GDE2 induces motor neuron differentiation in vivo. Science 309:2212–2215
15. Sabharwal P, Lee C, Park S, Rao M, Sockanathan S (2011) GDE2 regulates subtype-specific motor neuron generation through inhibition of Notch signaling. Neuron 71:1058–1068
16. Park S, Lee C, Sabharwal P, Zhang M, Meyers CL, Sockanathan S (2013) GDE2 promotes neurogenesis by glycosylphosphatidylinositol-anchor cleavage of RECK. Science 339:324–328
17. Cave C, Park S, Rodriguez M, Nakamura M, Hoke A, Pletnikov M, Sockanathan S (2017) GDE2 is essential for neuronal survival in the postnatal mammalian spinal cord. Mol Neurodegener 12:8
18. Yanaka N (2007) Mammalian glycerophosphodiester phosphodiesterases. Biosci Biotechnol Biochem 71:1811–1818
19. Nogusa Y, Fujioka Y, Komsato R, Kato N, Yanaka N (2004) Isolation and characterization of two serpentine membrane proteins containing glycerophosphodiester phosphodiesterase, GDE2 and GDE6. Gene 357:173–179
20. Yanaka N, Imai Y, Kawai E, Akiyama H, Wakimoto K, Nogusa Y, Kato N, Chiba H, Kotani E, Oomori K, Sakurai N (2003) Novel Membrane Protein Containing Glycerophosphodiester Phosphodiesterase Motif Is Transiently Expressed during Osteoblast Differentiation*
21. Matas-Rico E, van Veen M, Leyton-Puig D, van den Berg J, Koster J, Kedziora KM, Molenaar B, Weerts MJ, de Rink I, Medema RH et al (2016) Glycerophosphodiesterase GDE2 promotes neuroblastoma differentiation through glypican release and is a marker of clinical outcome. Cancer Cell 30:548–562
22. van Veen M, Matas-Rico E, van de Wetering K, Leyton-Puig D, Kedziora KM, De Lorenzi V, Stijl-Bultsma Y, van den Broek B, Jalink K, Sidenius N, et al. (2017) Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells. Elife, 6.
23. Gallazzini M, Ferraris JG, Burg MB (2008) GPD5S is a glycerophosphocho-line phosphodiesterase that osmotically regulates the osmoprotective organic osmolyte GPC. Proc Natl Acad Sci USA 105:11026–11031
24. Choi BR, Cave C, Na CH, Sockanathan S (2020) GDE2-dependent activation of canonical wnt signaling in neurons regulates oligodendrocyte maturation. Cell Rep 31:107540
25. Dobrovolski M, Cave C, Lesy-Meiners R, Lee C, Park S, Choi BR, Xiao B, Yang W, Sockanathan S (2020) GDE3 regulates oligodendrocyte precursor proliferation via release of soluble CNTFRa. Development, 147
26. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, Phatnani HP, Guamieri P, Caneda C, Rudersich N et al (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34:11929–11947
27. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX et al (1994) Motor neuron degeneration in mice that express a human Cu Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 369:2031–2041
28. Donaldson D, Goto J, O’Regan JP, Deng HK et al (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 363:59–62
29. Xia J, Poidevin M, Li X, Li Y, Shu L, Nelson DL, Li H, Hales CM, Gearing M, Wingo TS, Jin P (2013) Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc Natl Acad Sci USA 110:7778–7783
30. Nakamura M, Li Y, Choi BR, Matas-Rico E, Troncoso J, Takahashi C, Sockanathan S, et al. (2021) GDE2-RECK controls ADAM10 alpha-secretase-mediated cleavage of canonical wnt signaling in neurons regulating oligodendrocyte maturation. Cell Rep 31:107540
31. Hamton TG, Prevette D, Caress J, Oppenheim RW, Milligan C (2013) Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part I, background and methods. Brain Behav 3:335–350
32. Hamton TG, Prevette D, Caress J, Oppenheim RW, Milligan C (2013) Characterization of early pathogenesis in the SOD1(G93A) mouse model of ALS: part II, results and discussion. Brain Behav 3:431–457
33. Nakamura M, Li Y, Choi BR, Matas-Rico E, Troncoso J, Takahashi C, Sockanathan S (2021) GDE2-RECK controls ADAM10 alpha-secretase-mediated cleavage of amyloid precursor protein. Sci Transl Med, 13
31. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P et al (2019) STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47:D607–D613
32. Garman RH (2011) Histology of the central nervous system. Toxicol Pathol 39:22–35
33. Xiao S, McLean J, Robertson J (2006) Neuronal intermediate filaments and ALS: a new look at an old question. Biochim Biophys Acta 1762:1001–1012
34. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19:312–318
35. Barres BA (2008) The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60:430–440
36. Salgado-Polo F, van Veen M, van den Broek B, Jalink K, Leyton-Puig D, Perrakis A, Modenaar WH, Matas-Rico E (2020) Sequence-dependent trafficking and activity of GDE2, a GPI-specific phospholipase promoting neuronal differentiation. J Cell Sci, 133
37. Umoh ME, Dammer EB, Dai J, Duong DM, Lah JJ, Levey AI, Gearing M, Glass JD, Seyfried NT (2018) A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med 10:48–62
38. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, Takahashi R, Misawa H, Cleveland DW (2008) Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11:251–253
39. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, Takahashi R, Misawa H, Cleveland DW (2008) Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11:251–253
40. Wang L, Sharma K, Grisotti G, Roos RP (2009) The effect of mutant SOD1 dismutase activity on non-cell autonomous degeneration in familial amyotrophic lateral sclerosis. Neurobiol Dis 35:234–240
41. Dukkipati SS, Garrett TL, Elbasiouny SM (2018) The vulnerability of spinal motoneurons and soma size plasticity in a mouse model of amyotrophic lateral sclerosis. J Physiol 596:1723–1745

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.